Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Schmitt

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Langmuir : the ACS Journal of Surfaces and Colloids|August 11, 2005
Effect of time on the interfacial and foaming properties of beta-lactoglobulin/acacia gum electrostatic complexes and coacervates at pH 4.2Christophe Schmitt, Tânia Palma da Silva, Claudine Bovay, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|January 8, 2015
Complex equilibria, speciation, and heteroprotein coacervation of lactoferrin and β-lactoglobulinSean E Flanagan, Alexander J Malanowski, Ebru Kizilay, et al.
Clinical Pharmacokinetics|April 11, 2019
Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I TrialsKatrijn Bogman, Jochen Brumm, Carsten Hofmann, et al.
Cell Metabolism|August 3, 2017
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 DiabetesJuan Pablo Frias, Edward J Bastyr, Louis Vignati, et al.
Thrombosis and Haemostasis|October 21, 2020
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 StudyChristophe Schmitt, Joanne I Adamkewicz, Jin Xu, et al.
Clinical Pharmacology in Drug Development|May 21, 2020
Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese SubjectsHaiyan Li, Weijiang Zhang, Claire Petry, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 4, 2021
Low immunogenicity of emicizumab in persons with haemophilia AChristophe Schmitt, Thomas Emrich, Sammy Chebon, et al.
Research and Practice in Thrombosis and Haemostasis|March 14, 2022
Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5)Renchi Yang, Shujie Wang, Xuefeng Wang, et al.
Gastroenterologie Clinique Et Biologique|March 27, 2003
[An inter-laboratory study of anti-HCV antibody detection in saliva samples]Damien Lucidarme, Anne Decoster, Catherine Delamare, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2022
Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia AChristophe Schmitt, Maria Elisa Mancuso, Tiffany Chang, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Langmuir : the ACS Journal of Surfaces and Colloids|August 11, 2005
Effect of time on the interfacial and foaming properties of beta-lactoglobulin/acacia gum electrostatic complexes and coacervates at pH 4.2Christophe Schmitt, Tânia Palma da Silva, Claudine Bovay, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|January 8, 2015
Complex equilibria, speciation, and heteroprotein coacervation of lactoferrin and β-lactoglobulinSean E Flanagan, Alexander J Malanowski, Ebru Kizilay, et al.
Clinical Pharmacokinetics|April 11, 2019
Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I TrialsKatrijn Bogman, Jochen Brumm, Carsten Hofmann, et al.
Cell Metabolism|August 3, 2017
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 DiabetesJuan Pablo Frias, Edward J Bastyr, Louis Vignati, et al.
Thrombosis and Haemostasis|October 21, 2020
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 StudyChristophe Schmitt, Joanne I Adamkewicz, Jin Xu, et al.
Clinical Pharmacology in Drug Development|May 21, 2020
Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese SubjectsHaiyan Li, Weijiang Zhang, Claire Petry, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 4, 2021
Low immunogenicity of emicizumab in persons with haemophilia AChristophe Schmitt, Thomas Emrich, Sammy Chebon, et al.
Research and Practice in Thrombosis and Haemostasis|March 14, 2022
Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5)Renchi Yang, Shujie Wang, Xuefeng Wang, et al.
Gastroenterologie Clinique Et Biologique|March 27, 2003
[An inter-laboratory study of anti-HCV antibody detection in saliva samples]Damien Lucidarme, Anne Decoster, Catherine Delamare, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2022
Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia AChristophe Schmitt, Maria Elisa Mancuso, Tiffany Chang, et al.
Pageof 8